Dates: July 12-15, 2026
Location: ExCeL London, United Kingdom
Organizer: [Alzheimer's Association](https://www.alz.org/)[@alzorg]
Overview
flowchart TD
events_aaic_2026_company_prese["AAIC 2026 Company Presentations"]
style events_aaic_2026_company_prese fill:#4fc3f7,stroke:#333,color:#000
events_aaic_2026_com_0["Conference Context"]
events_aaic_2026_company_prese -->|"includes"| events_aaic_2026_com_0
style events_aaic_2026_com_0 fill:#81c784,stroke:#333,color:#000
events_aaic_2026_com_1["Importance of AAIC for Industry"]
events_aaic_2026_company_prese -->|"includes"| events_aaic_2026_com_1
style events_aaic_2026_com_1 fill:#ef5350,stroke:#333,color:#000
events_aaic_2026_com_2["AAIC 2026 Industry Track Overview"]
events_aaic_2026_company_prese -->|"includes"| events_aaic_2026_com_2
style events_aaic_2026_com_2 fill:#ffd54f,stroke:#333,color:#000
events_aaic_2026_com_3["Company Presentation Types"]
events_aaic_2026_company_prese -->|"includes"| events_aaic_2026_com_3
style events_aaic_2026_com_3 fill:#ce93d8,stroke:#333,color:#000
events_aaic_2026_com_4["Corporate Symposia"]
events_aaic_2026_company_prese -->|"includes"| events_aaic_2026_com_4
style events_aaic_2026_com_4 fill:#4fc3f7,stroke:#333,color:#000
events_aaic_2026_com_5["Booth Presentations and Exhibition"]
events_aaic_2026_company_prese -->|"includes"| events_aaic_2026_com_5
style events_aaic_2026_com_5 fill:#81c784,stroke:#333,color:#000
...Dates: July 12-15, 2026
Location: ExCeL London, United Kingdom
Organizer: [Alzheimer's Association](https://www.alz.org/)[@alzorg]
Overview
Mermaid diagram (expand to render)
The AAIC Company Presentations provide a critical platform for pharmaceutical and biotechnology companies to present their Alzheimer's disease and dementia research programs, clinical trial results, pipeline updates, and strategic directions to the global research community. As the world's largest Alzheimer's research conference, AAIC attracts presentations from major pharmaceutical companies, innovative biotechnology firms, and emerging biotech startups all seeking to showcase their therapeutic approaches["@aaic"].
This page covers the company presentations expected at AAIC 2026, their therapeutic pipelines, clinical trial programs, and the scientific data being presented. The conference serves as a crucial inflection point for companies to share data that may influence investment decisions, research collaborations, and the future direction of Alzheimer's therapeutic development.
Conference Context
Importance of AAIC for Industry
The Alzheimer's Association International Conference serves multiple critical functions for companies in the Alzheimer's therapeutics space:
Data Disclosure Forum: Companies present late-breaking clinical trial results to a global audience of researchers, clinicians, and investors
Scientific Engagement: Direct interaction with academic researchers enables feedback on programs and identification of collaboration opportunities
Competitive Intelligence: Companies can assess the broader landscape and identify emerging approaches
Talent Recruitment: Networking with leading researchers supports recruitment efforts
Regulatory Interaction: FDA officials often attend, providing opportunities for regulatory dialogueAAIC 2026 Industry Track Overview
AAIC 2026 features a dedicated industry track with multiple presentation formats designed to showcase company programs comprehensively.
Company Presentation Types
Corporate Symposia
Corporate symposia are hour-long, sponsored educational sessions that provide in-depth coverage of specific therapeutic approaches or clinical programs:
- Sponsored Educational Sessions: CME-accredited presentations on disease mechanisms, therapeutic targets, or clinical approaches
- Clinical Trial Data Presentations: Detailed results from Phase II and Phase III trials
- Research Pipeline Overviews: Comprehensive reviews of company programs across discovery through clinical development
- Key Opinion Leader Presentations: External experts presenting company-sponsored research
Corporate symposia at AAIC typically feature prominent companies with late-stage programs and are often the venue for primary data disclosures.
Booth Presentations and Exhibition
The exhibition floor at AAIC provides companies with interactive spaces to engage with attendees:
- Product Information: Educational materials on approved therapies and clinical programs
- Clinical Trial Recruitment: Information about enrolling studies and eligibility criteria
- Scientific Discussions: One-on-one meetings with medical affairs and research personnel
- Technology Demonstrations: Displays of diagnostic tools, biomarker assays, and digital health solutions
Major exhibition booths are staffed by medical affairs teams, clinical development personnel, and often principal investigators conducting company-sponsored trials.
Partnering Events
AAIC facilitates business development through structured partnering:
- Business Development Meetings: Pre-scheduled one-on-one meetings between company representatives and potential partners
- Collaboration Opportunities: Presentations of co-development or licensing opportunities
- Investor Sessions: Dedicated times for investment analysts to meet with company management
- Academic Collaborations: Opportunities for academic investigators to engage with company research teams
The Alzheimer's Drug Discovery Foundation (ADDF) and other organizations facilitate partnering activities during the conference.
Major Pharmaceutical Partners Expected
Eisai and Biogen (Leqembi)
Leqembi (lecanemab) represents the first approved disease-modifying therapy that demonstrates meaningful clinical benefit in early Alzheimer's disease[@leqembi]. Expected presentations:
- TRAILBLAZER-ALZ 2 Trial Extensions: Long-term follow-up data from the confirmatory Phase III trial
- Real-World Evidence: Post-approval effectiveness data
- Combination Approaches: Studies combining lecanemab with other therapeutic modalities
- Subgroup Analyses: Detailed efficacy data in various patient populations
- Biomarker Correlations: tauPET and CSF biomarker data supporting mechanism
Leqembi, jointly developed by Eisai and Biogen, received full FDA approval in July 2023 and has been approved in Japan, China, South Korea, and is under review in other markets. The companies are expected to present additional analyses from the TRAILBLAZER program at AAIC 2026.
Eli Lilly (donanemab/kisunla)
Donanemab (Kisunla) received FDA approval in 2024 for treatment of early symptomatic Alzheimer's disease[@donanemab]. Expected presentations:
- TRAILBLAZER-ALZ 3 Trial: Primary prevention trial in cognitively normal individuals with elevated amyloid
- TRAILBLAZER-ALZ 2 Extension: Long-term outcomes data
- TRAILBLAZER-ALZ 4: Head-to-head comparison with Aduhelm
- Subpopulation Analyses: Efficacy in ApoE4 carriers, downs syndrome patients
- ARIA Management: Strategies for managing amyloid-related imaging abnormalities
Eli Lilly's Alzheimer's program represents one of the most advanced pipelines in the industry, with donanemab approved and additional programs in development.
Roche/Genentech
Roche maintains a substantial Alzheimer's pipeline with multiple programs at various stages[@roche]:
- Gantenerumab (crenezumab): Ongoing development program
- Anti-tau Programs: Multiple tau-targeting antibodies in development
- Biomarker Partnerships: Collaboration with diagnostic companies
- Combination Strategies: Approaches combining amyloid removal with other mechanisms
Roche presents regularly at AAIC and is expected to share updates on their Alzheimer's research programs.
Johnson & Johnson
Johnson & Johnson has an evolving neuroscience portfolio with interest in Alzheimer's:
- JNJ-63733657: Anti-tau antibody program
- Neurodegeneration Pipeline: Broader CNS programs
- Diagnostic Collaborations: Partnerships in biomarker development
Merck (MSD)
Merck's neuroscience division focuses on multiple CNS conditions:
- Verubecestat Updates: BACE inhibitor program data (if presented)
- Early Pipeline: Novel approaches to Alzheimer's modification
- Biomarker Work: CSF and blood-based biomarker development
Biotechnology Companies Expected
AC Immune
AC Immune is a Swiss biotechnology company with a broad Alzheimer's pipeline[@acimmune]:
- Crenezumab: Anti-amyloid antibody (in collaboration with Roche)
- ACI-35: Phospho-tau vaccine
- ACI-24: Anti-amyloid vaccine
- SAM-760: Anti-tau antibody
AC Immune presents regularly at AAIC and is expected to share updates on their vaccine and antibody programs.
Prothelia
Prothelia focuses on proteostasis in neurodegeneration:
- Synaptic Protection Programs: Approaches to preserve synaptic function
- Protein Aggregation Inhibitors: Small molecule programs
Cerevel Therapeutics
Cerevel has multiple neuroscience programs:
- CVL-231: Muscarinic agonist for cognitive enhancement
- Parkinson's Programs: Dopamine receptor modulators
- Other CNS Programs: Anxiety, depression pipelines
Vida Therapeutics
Emerging company with focus on:
- Cell Therapy Approaches: Cellular-based treatments for neurodegeneration
- Regenerative Medicine: Novel therapeutic modalities
Additional Biotechnology Companies
The AAIC exhibition typically includes numerous additional biotech companies:
- Prothelia: Synaptic protection
- Vida Therapeutics: Cell-based approaches
- Cerecin: Metabolic approaches to neurodegeneration
- NeuroPhage: Broad-spectrum aggregation inhibitors
Pipeline Summary by Therapeutic Approach
Amyloid-Targeting Therapies
| Company | Agent | Mechanism | Phase | Status |
|---------|-------|------------|-------|--------|
| Eisai/Biogen | Lecanemab | Anti-amyloid protofibril | Approved | Commercial |
| Eli Lilly | Donanemab | Anti-amyloid plaque | Approved | Commercial |
| Roche | Gantenerumab | Anti-amyloid aggregate | III | Ongoing |
| AC Immune | Crenezumab | Anti-amyloid | II | Ongoing |
| Prothelia | PR-004 | BACE inhibitor | I | Ongoing |
Tau-Targeting Therapies
| Company | Agent | Mechanism | Phase | Status |
|---------|-------|------------|-------|--------|
| Eli Lilly | Donanemab | Anti-tau | Approved | Commercial |
| Roche | Semorinemab | Anti-tau | II | Ongoing |
| AC Immune | SAM-760 | Anti-tau | II | Ongoing |
| Janssen | JNJ-63733657 | Anti-tau | I | Ongoing |
Neuroprotective and Disease-Modifying Approaches
| Company | Agent | Mechanism | Phase | Status |
|---------|-------|------------|-------|--------|
| AC Immune | ACI-35 | Phospho-tau vaccine | II | Ongoing |
| Cerevel | CVL-231 | Muscarinic M1 agonist | II | Ongoing |
Clinical Trial Results Expected
Late-Breaking Presentations
AAIC features late-breaking abstract presentations where companies and investigators present primary endpoint data from major trials:
- Extension Studies: Long-term follow-up from pivotal trials
- Biomarker Correlations: CSF, PET, and blood-based biomarker data
- Subgroup Analyses: Efficacy in various patient subpopulations
Publication Implications
Data presented at AAIC often leads to subsequent peer-reviewed publications, with company-sponsored trials frequently published in high-impact journals following conference presentation.
Scientific Highlights to Expect
Biomarker Discussions
- Amyloid PET Standardization: Centiloid scale adoption
- Tau PET Interpretation: Regional tau and clinical correlation
- Fluid Biomarkers: p-tau217, p-tau181, NFL in clinical practice
- Combination Biomarkers: Multi-marker panels for patient selection
Clinical Outcome Measures
- ADAS-Cob: Alzheimer's Disease Assessment Scale
- Clinical Dementia Rating: CDR scores in trials
- Cognitive Function Batteries: Novel endpoints being validated
- Real-World Outcomes: Functional measures in clinical practice
Regulatory Considerations
- FDA Guidance: Updates on regulatory expectations
- Accelerated Approval: Lessons from amyloid antibodies
- Clinical Endpoints: FDA perspectives on approvable endpoints
Industry Networking Opportunities
- Reception Hosts: Company-sponsored networking receptions
- Investor Days: Formal investor presentations
- Investigator Meetings: Principal investigator gatherings
Academic-Industry Collaboration
- Research Grants: Industry funding for academic research
- Data Sharing Initiatives: Consortium participation
- Biomarker Development: Collaborative assay development
Future Directions in Alzheimer's Therapeutics
Emerging Modalities
- Gene Therapy: Approaches to deliver therapeutic genes
- Cell Therapy: Cellular replacement strategies
- Small Molecule Modulators: Novel mechanisms beyond amyloid
- Combination Approaches: Multi-target therapeutic strategies
Precision Medicine
- Biomarker-Driven Selection: Patient selection based on biomarkers
- Personalized Approaches: Tailored therapeutic interventions
- Prevention Trials: Preclinical disease modification
Related NeuroWiki Content
Alzheimer's Disease Treatments
- [Leqembi (lecanemab)](/therapeutics/leqembi)
- [Donanemab](/therapeutics/donanemab)
- [Aduhelm](/therapeutics/aduhelm)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [AAIC 2026 Conference](/events/aaic-2026)
- [AAIC 2026 Plenary Sessions](/events/aaic-2026-plenary-sessions)
- [AAIC 2026 Scientific Sessions](/events/aaic-2026-scientific-sessions)
- [AAIC 2026 Clinical Trials](/events/aaic-2026-clinical-trials)
- [Conference Index](/events/conference-index)
Therapeutic Mechanisms
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- [Tau Pathology in AD](/mechanisms/tau-pathology-ad)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation)
External Resources
- [AAIC 2026 Official Website](https://aaic.alz.org)
- [AAIC 2026 Program](https://aaic.alz.org/program)[@aaic]
- [Alzheimer's Association](https://www.alz.org/)[@alzorg]
- [Leqembi FDA Approval](https://www.fda.gov/drugs/news-events-human-drug-alerts/fda-approves-new-treatment-alzheimers-disease)[@leqembi]
- [Donanemab FDA Approval](https://www.fda.gov/drugs/fda-approves-donanemab-azilect-alzheimers-disease)[@donanemab]
References
[AAIC 2026 Official Program (2026)](https://aaic.alz.org/program)
[Alzheimer's Association](https://www.alz.org/)
[FDA Approves Leqcanemab for Alzheimer's Disease (2023)](https://www.fda.gov/drugs/news-events-human-drug-alerts/fda-approves-new-treatment-alzheimers-disease)
[FDA Approves Donanemab for Alzheimer's Disease (2024)](https://www.fda.gov/drugs/fda-approves-donanemab-azilect-alzheimers-disease)
[AC Immune Pipeline](https://www.acimmune.com/pipeline/)
[Roche Research Pipeline](https://www.roche.com/research/pipeline)